Trimethyl Lock-2Cl (TML-2Cl): A self-cyclizing adapter for molecular release in antibody-drug conjugates

Key Points

• Molecular release is enhanced through the use of a self-cyclizing adapter, improving therapeutic efficacy.
• The trimethyl lock-2Cl demonstrates significant efficiency in antibody-drug conjugates compared to conventional methods.
• Assessment using bioconjugation techniques reveals improved release dynamics and targeting precision.
• Such findings support the potential for better-targeted therapies, although further validation in clinical settings is necessary.